Major Pharmaceutical and Biotechnology Companies of the World 2012

Editors Layla Comstive Susan Hoernig Sue Ward

Australia • Brazil • Japan • Korea • Mexico • Singapore • Spain • United Kingdom • United States

Contents Major Pharmaceutical and Biotechnology Companies of the World 2012 Africa (South of the Sahara) Angola . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Benin . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Botswana . . . . . . . . . . . . . . . . . . . . . . . . 1 Burkina Faso . . . . . . . . . . . . . . . . . . . . . . 1 Cameroon . . . . . . . . . . . . . . . . . . . . . . . . 1 Cape Verde . . . . . . . . . . . . . . . . . . . . . . . 1 Democratic Republic of the Congo . . . . . 1 Ethiopia . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Gabon . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Ghana . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Ivory Coast . . . . . . . . . . . . . . . . . . . . . . . 3 Kenya . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Lesotho . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Madagascar . . . . . . . . . . . . . . . . . . . . . . 4 Malawi . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Mali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Mauritius . . . . . . . . . . . . . . . . . . . . . . . . . 5 Mozambique . . . . . . . . . . . . . . . . . . . . . . 5 Niger . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Nigeria . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Republic of the Congo . . . . . . . . . . . . . . 7 Senegal . . . . . . . . . . . . . . . . . . . . . . . . . . 7 South Africa . . . . . . . . . . . . . . . . . . . . . . 8 Swaziland . . . . . . . . . . . . . . . . . . . . . . . 15 Togo . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Uganda . . . . . . . . . . . . . . . . . . . . . . . . . 16 Zambia . . . . . . . . . . . . . . . . . . . . . . . . . 16 Zimbabwe . . . . . . . . . . . . . . . . . . . . . . . 16 Arab World Algeria . . . . . . . . . . . . . . . . . . . . . . . . . 16 Bahrain . . . . . . . . . . . . . . . . . . . . . . . . . 17 Egypt . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Gaza and West Bank . . . . . . . . . . . . . . 23 Iraq . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Jordan . . . . . . . . . . . . . . . . . . . . . . . . . 24 Kuwait . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Lebanon . . . . . . . . . . . . . . . . . . . . . . . . 30 Libyan Arab Jamahiriya . . . . . . . . . . . . 32 Mauritania . . . . . . . . . . . . . . . . . . . . . . 32 Morocco . . . . . . . . . . . . . . . . . . . . . . . . 32 Oman . . . . . . . . . . . . . . . . . . . . . . . . . . 34 Qatar . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Saudi Arabia . . . . . . . . . . . . . . . . . . . . . 36 Sudan . . . . . . . . . . . . . . . . . . . . . . . . . . 45 Syrian Arab Republic . . . . . . . . . . . . . . 46 Tunisia . . . . . . . . . . . . . . . . . . . . . . . . . 48 United Arab Emirates . . . . . . . . . . . . . . 49 UAE (Abu Dhabi) . . . . . . . . . . . . . . . . . . 49 UAE (Dubai) . . . . . . . . . . . . . . . . . . . . . 49 UAE (Fujairah) . . . . . . . . . . . . . . . . . . . . 51 UAE (Ras Al Khaimah) . . . . . . . . . . . . . 51 UAE (Sharjah) . . . . . . . . . . . . . . . . . . . . 52 Yemen . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Asia and Australasia Australia . . . . . . . . . . . . . . . . . . . . . . . . 53 Bangladesh . . . . . . . . . . . . . . . . . . . . . . 63 Hong Kong SAR . . . . . . . . . . . . . . . . . . 65 India . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Indonesia . . . . . . . . . . . . . . . . . . . . . . 115

Iran . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 Japan . . . . . . . . . . . . . . . . . . . . . . . . . 122 Malaysia . . . . . . . . . . . . . . . . . . . . . . . 153 Mongolia . . . . . . . . . . . . . . . . . . . . . . . 165 Myanmar . . . . . . . . . . . . . . . . . . . . . . 165 Nepal . . . . . . . . . . . . . . . . . . . . . . . . . 165 New Zealand . . . . . . . . . . . . . . . . . . . 166 North Korea . . . . . . . . . . . . . . . . . . . . 169 Pakistan . . . . . . . . . . . . . . . . . . . . . . . 169 Papua New Guinea . . . . . . . . . . . . . . . 171 People’s Republic of China . . . . . . . . 172 Philippines . . . . . . . . . . . . . . . . . . . . . 200 Singapore . . . . . . . . . . . . . . . . . . . . . . 204 South Korea . . . . . . . . . . . . . . . . . . . . 211 Sri Lanka . . . . . . . . . . . . . . . . . . . . . . 225 Taiwan . . . . . . . . . . . . . . . . . . . . . . . . 226 Thailand . . . . . . . . . . . . . . . . . . . . . . . 235 Vietnam . . . . . . . . . . . . . . . . . . . . . . . 238 Eastern Europe and the Commonwealth of Independent States Albania . . . . . . . . . . . . . . . . . . . . . . . . 242 Armenia . . . . . . . . . . . . . . . . . . . . . . . 242 Azerbaijan . . . . . . . . . . . . . . . . . . . . . . 242 Belarus . . . . . . . . . . . . . . . . . . . . . . . . 243 Bosnia and Herzegovina . . . . . . . . . . . 243 Croatia . . . . . . . . . . . . . . . . . . . . . . . . 244 Georgia . . . . . . . . . . . . . . . . . . . . . . . . 245 Kazakhstan . . . . . . . . . . . . . . . . . . . . . 246 Macedonia . . . . . . . . . . . . . . . . . . . . . 246 Moldova . . . . . . . . . . . . . . . . . . . . . . . 247 Montenegro . . . . . . . . . . . . . . . . . . . . 247 Russia . . . . . . . . . . . . . . . . . . . . . . . . . 247 Serbia . . . . . . . . . . . . . . . . . . . . . . . . . 261 Ukraine . . . . . . . . . . . . . . . . . . . . . . . . 262 Uzbekistan . . . . . . . . . . . . . . . . . . . . . 265 Europe Austria . . . . . . . . . . . . . . . . . . . . . . . . 266 Belgium . . . . . . . . . . . . . . . . . . . . . . . 271 Bulgaria . . . . . . . . . . . . . . . . . . . . . . . 280 Cyprus . . . . . . . . . . . . . . . . . . . . . . . . 281 Czech Republic . . . . . . . . . . . . . . . . . . 282 Denmark . . . . . . . . . . . . . . . . . . . . . . . 287 Estonia . . . . . . . . . . . . . . . . . . . . . . . . 295 Finland . . . . . . . . . . . . . . . . . . . . . . . . 295 France . . . . . . . . . . . . . . . . . . . . . . . . 299 Germany . . . . . . . . . . . . . . . . . . . . . . . 334 Greece . . . . . . . . . . . . . . . . . . . . . . . . 365 Hungary . . . . . . . . . . . . . . . . . . . . . . . 370 Iceland . . . . . . . . . . . . . . . . . . . . . . . . 376 Israel . . . . . . . . . . . . . . . . . . . . . . . . . . 377 Italy . . . . . . . . . . . . . . . . . . . . . . . . . . . 383 Latvia . . . . . . . . . . . . . . . . . . . . . . . . . 395 Liechtenstein . . . . . . . . . . . . . . . . . . . 396 Lithuania . . . . . . . . . . . . . . . . . . . . . . . 396 Luxembourg . . . . . . . . . . . . . . . . . . . . 396 Monaco . . . . . . . . . . . . . . . . . . . . . . . 397 Netherlands . . . . . . . . . . . . . . . . . . . . 397 Norway . . . . . . . . . . . . . . . . . . . . . . . . 405 Poland . . . . . . . . . . . . . . . . . . . . . . . . 409 Portugal . . . . . . . . . . . . . . . . . . . . . . . 418 Republic of Ireland . . . . . . . . . . . . . . . 423

Romania . . . . . . . . . . . . . . . . . . . . . . . 429 Slovakia . . . . . . . . . . . . . . . . . . . . . . . 431 Slovenia . . . . . . . . . . . . . . . . . . . . . . . 433 Spain . . . . . . . . . . . . . . . . . . . . . . . . . 435 Sweden . . . . . . . . . . . . . . . . . . . . . . . 455 Switzerland . . . . . . . . . . . . . . . . . . . . . 463 Turkey . . . . . . . . . . . . . . . . . . . . . . . . . 482 UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485 Latin America Argentina . . . . . . . . . . . . . . . . . . . . . . 513 Belize . . . . . . . . . . . . . . . . . . . . . . . . . 516 Bolivia . . . . . . . . . . . . . . . . . . . . . . . . . 516 Brazil . . . . . . . . . . . . . . . . . . . . . . . . . 517 CARIBBEAN - Antigua and Barbuda . . 528 CARIBBEAN - Aruba . . . . . . . . . . . . . . 528 CARIBBEAN - Bahamas . . . . . . . . . . . 528 CARIBBEAN - Barbados . . . . . . . . . . . 529 CARIBBEAN - Bermuda . . . . . . . . . . . 529 CARIBBEAN - Cayman Islands . . . . . . 529 CARIBBEAN - Dominican Republic . . . 529 CARIBBEAN - Grenada . . . . . . . . . . . . 530 CARIBBEAN - Jamaica . . . . . . . . . . . . 530 CARIBBEAN - Puerto Rico . . . . . . . . . 531 CARIBBEAN - St Lucia . . . . . . . . . . . . 531 CARIBBEAN - St Vincent and the Grenadines . . . . . . . . . . . . . . . . . . . . 531

IV

CARIBBEAN - Trinidad and Tobago . . 531 Chile . . . . . . . . . . . . . . . . . . . . . . . . . . 532 Colombia . . . . . . . . . . . . . . . . . . . . . . 535 Costa Rica . . . . . . . . . . . . . . . . . . . . . 537 Curacao . . . . . . . . . . . . . . . . . . . . . . . 537 Ecuador . . . . . . . . . . . . . . . . . . . . . . . 538 El Salvador . . . . . . . . . . . . . . . . . . . . . 538 French Guyana . . . . . . . . . . . . . . . . . . 538 Guatemala . . . . . . . . . . . . . . . . . . . . . 539 Guyana . . . . . . . . . . . . . . . . . . . . . . . . 539 Mexico . . . . . . . . . . . . . . . . . . . . . . . . 539 Nicaragua . . . . . . . . . . . . . . . . . . . . . . 546 Panama . . . . . . . . . . . . . . . . . . . . . . . 546 Paraguay . . . . . . . . . . . . . . . . . . . . . . 547 Peru . . . . . . . . . . . . . . . . . . . . . . . . . . 547 Suriname . . . . . . . . . . . . . . . . . . . . . . 548 Uruguay . . . . . . . . . . . . . . . . . . . . . . . 548 Venezuela . . . . . . . . . . . . . . . . . . . . . . 549 North America Canada . . . . . . . . . . . . . . . . . . . . . . . . 551 USA . . . . . . . . . . . . . . . . . . . . . . . . . . 557 Indexes Alphabetical Index . . . . . . . . . . . . . . . 595 Index by Country . . . . . . . . . . . . . . . . 625

00936 CHEMI DAROU INDUSTRIAL COMPANY Status: Private Company

00936 CHEMI DAROU INDUSTRIAL COMPANY Address: PO Box 16575-361, Next to Saipa Co, 3km Mark, Abali Road, Tehran International tel: +98 (21) 7733 0291 International fax: +98 (21) 7733 6458 Company email: [email protected] Website: www.chemidarou.com Board of Directors: Ali Jabbari (Managing Director) PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals, polyvinyl acetate resins and textile auxiliaries Ticker Symbol: KIMI1 Stock Exchange: TSE ISIN: IRO1KIMI0001 Status: Public Company Date of Establishment: 1965 No of Employees: 350 Financial Information: 20.3.10 20.3.11 IR’000 IR’000 Sales turnover 498,833,000 450,475,000 Profit before tax 143,277,000 134,427,000 Profit after tax 112,370,000 115,478,000 Earnings per share IR936 IR481 Share capital 120,000,000 240,000,000 Shareholders’ equity 333,545,000 370,223,000

IRAN 00939 DAMLORAN PHARMACEUTICAL COMPANY Address: 7 Parvin Street, West Dr Fatemi Avenue, 14186 Tehran International tel: +98 (21) 6694 5732; +98 (21) 939 690; +98 (21) 885 6907 International fax: +98 (662) 6694 5736 (Factory); +98 (21) 651325 Telex: 212710 DVPL IR Company email: [email protected] Website: www.damloran.com/ Board of Directors: Ahmad Karbasi (Managing Director) PRINCIPAL ACTIVITIES: Manufacture and distribution of veterinary pharmaceuticals Trade Names: Damloran Ticker Symbol: DAML1 Stock Exchange: TSE ISIN: IRO1DAML0001 Status: Public Company Date of Establishment: 1983 No of Employees: 220 Financial Information: 20.3.10 20.3.11 IR’000 IR’000 Sales turnover 300,752,000 367,850,000 Profit before tax 61,988,000 70,110,000 Profit after tax 48,396,000 54,654,000 Earnings per share IR1,367 IR1,544 Share capital 35,400,000 35,400,000 Shareholders’ equity 113,486,000 126,710,000

00937 CINNAGEN COMPANY

00940 DAROU PAKHSH (HOLDING) COMPANY

Address: 5th Floor, 56 Azimi St, Phase 1, Shahrak Ekbatan, Tehran International tel: +98 (211) 4466 6203 International fax: +98 (211) 4466 4991 Company email: [email protected];[email protected] Website: www.cinnagen.com Management: Dr Haleh Hamedifar (President) PRINCIPAL ACTIVITIES: Molecular biology and biotechnology company, producing diagnostic/research reagents including blood grouping reagents, PCR kits and reagents, HIV kits, T3 T4 kits, LHRH, molecular biology reagents and CA, PH and CL diagnostic kits Status: Private Company Date of Establishment: 1994

Address: Darou Pakhsh Street, 18km Mark, Tehran-Karaj Highway, Tehran International tel: +98 (21) 4498 6815 International fax: +98 (21) 4498 7314 Company email: [email protected] Website: www.dppharma.ir Board of Directors: Ahmad Sheybani (Managing Director) PRINCIPAL ACTIVITIES: Investment holding company with subsidiaries involved in the manufacture and marketing of pharmaceuticals Subsidiary Companies: (100% owned unless stated): Darou Pakhsh Pharmaceuticals Company; Darou Pakhsh Pharmaceuticals Manufacturing Company Ticker Symbol: DARO1 Stock Exchange: TSE ISIN: IRO1DARO0001 Status: Public Company No of Employees: 3,420 Financial Information: 20.3.10 20.3.11 IR’000 IR’000 Income 580,950,000 701,416,000 Profit before tax 574,325,000 729,997,000 Profit after tax 573,869,000 727,834,000 Earnings per share IR956 IR1,213 Share capital 600,000,000 600,000,000 Shareholders’ equity 1,349,373,000 1,583,474,000

00938 COSAR PHARMACEUTICAL COMPANY Address: 32, 6th Alley, Ahmad Qasir Street, Abbas Abad Street, 15147-17811 Tehran International tel: +98 (211) 8873 7401 International fax: +98 (211) 8873 2664 Telex: 223243 CSPH-IR Website: www.cosarpharm.com Board of Directors: Faramarz Shariat (Managing Director) PRINCIPAL ACTIVITIES: Manufacture and idstribution of pharmaceuticals, particularly antibiotic finished products such as Ampicillin, Amoxicillin and Cloxacillin Major Products: Antibiotics oral forms Trade Names: Irapen, Iramox, Cloxiran, Co-Amoxiclav, Garlet Principal Banks: Bank Tejarat Auditors: Rahbord Argham Co Ticker Symbol: DKSR1 Stock Exchange: TSE ISIN: IRO1DKSR0001 Status: Public Company Date of Establishment: 1975 No of Employees: 230 Financial Information: 20.3.10 20.3.11 IR’000 IR’000 Sales turnover 424,078,000 295,540,000 Profit before tax 64,944,000 45,264,000 Profit after tax 52,200,000 45,264,000 Earnings per share IR387 IR251 Share capital 135,000,000 180,000,000 Shareholders’ equity 230,911,000 220,875,000

120

Financial Information: Sales turnover Profit before tax Profit after tax Earnings per share Share capital Shareholders’ equity

20.3.10 IR’000 266,136,000 25,525,000 19,956,000 IR570 35,000,000 57,981,000

20.3.11 IR’000 280,825,000 36,521,000 28,779,000 IR822 35,000,000 68,860,000

00942 DAROU PAKHSH PHARMACEUTICALS MANUFACTURING COMPANY Address: Darou Pakhsh Street, 18km Mark, Tehran-Karaj Highway, Tehran International tel: +98 (21) 4498 6815 International fax: +98 (21) 4498 7314 Company email: [email protected] Website: www.dppharma.ir PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals Parent Company: Darou Pakhsh (Holding) Company (00940) Ticker Symbol: DPAK1 Stock Exchange: TSE ISIN: IRO1DPAK0001 Status: Public Company Principal Shareholders: Darou Pakhsh (Holding) Company Financial Information: 20.3.10 20.3.11 IR’000 IR’000 Sales turnover 1,003,667,000 1,101,409,000 Profit before tax 264,658,000 274,454,000 Profit after tax 200,316,000 213,605,000 Earnings per share IR2,003 IR1,068 Share capital 100,000,000 200,000,000 Shareholders’ equity 389,685,000 433,290,000

00943 DOCTOR ABIDI LABORATORIES COMPANY Address: 8km Mark, Karaj Special Road Boulevard, Tehran International tel: +98 (21) 4450 4785 International fax: +98 (21) 4450 4787 Company email: [email protected] Website: www.doctor-abidi.com Board of Directors: M Hasan Baradaran Ghasemi (Managing Director) PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals Ticker Symbol: ABDI1 Stock Exchange: TSE ISIN: IRO1ABDI0001 Status: Public Company No of Employees: 250 Financial Information: 20.3.10 20.3.11 IR’000 IR’000 Sales turnover 376,023,000 443,887,000 Profit before tax 121,529,000 102,595,000 Profit after tax 98,894,000 80,810,000 Earnings per share IR1,766 IR1,443 Share capital 56,000,000 56,000,000 Shareholders’ equity 190,291,000 213,901,000

00941 DAROU PAKHSH PHARMACEUTICALS COMPANY

00944 EXIR PHARMACEUTICAL COMPANY

Address: Darou Pakhsh Street, 18km Mark, Tehran-Karaj Highway, Tehran International tel: +98 (21) 4498 6815 International fax: +98 (21) 4498 7314 Company email: [email protected] Website: www.dppharma.ir PRINCIPAL ACTIVITIES: Wholesale of pharmaceuticals Parent Company: Darou Pakhsh (Holding) Company (00940) Ticker Symbol: DDPK1 Stock Exchange: TSE ISIN: IRO1DDPK0001 Status: Public Company Principal Shareholders: Darou Pakhsh (Holding) Company No of Employees: 260

Address: PO Box 14335-379, 22 Rahmati Alley, Vali-e Asr, Tehran International tel: +98 (21) 8891 8461 International fax: +98 (21) 8889 9358 Company email: [email protected] Website: exir.co.ir Board of Directors: Gholam Hossain Farzandi (Managing Director) PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals Ticker Symbol: EXIR1 Stock Exchange: TSE ISIN: IRO1EXIR0001 Status: Public Company No of Employees: 590

03590 ACINO HOLDING AG Company email: [email protected] Website: www.abbott.ch Company Registration Number: CH-280.3.910.125-8 Management Board: Jacopo Andreose (Chairman), Robert Lüthi (Member), Peter Reinert (Member) PRINCIPAL ACTIVITIES: Development and manufacture of pharmaceuticals and nutritional products, and products for diabetes care, laboratory diagnostics, vascular disease treatment and molecular diagnostics. ISO 9001 and ISO 14001 certified Company History: The company was previously known as Knoll AG and subsequently as Abbott Liestal AG Branch Offices: Altishofen; Beringen Parent Company: Abbott Laboratories, USA Principal Banks: UBS Auditors: Deloitte AG Status: Private Company Principal Shareholders: Abbott Laboratories, USA (100%) Date of Establishment: 1893 No of Employees: 140 (Company) 300 (Switzerland)

03590 ACINO HOLDING AG Address: Erlenstrasse 1, 4058 Basel International tel: +41 (61) 338 60 00; +41 (61) 775 80 10 International fax: +41 (61) 338 60 06 Company email: [email protected] Website: www.acino-pharma.com Company Registration Number: CH-270.3.002.367-6 Board of Directors: Luzi Andreas von Bidder (Chairman), Dr René Muttenzer (Vice Chairman), Dr Anders Härfstrand (Director), Hans Peter Hasler (Director), Jürg Michel (Director) Executive Board: Peter Burema (Chief Executive Officer), Dr Jean-Daniel Bonny (Head of Research and Development), Dr Annette Eschler (Head of Business Development), Jörg Gebhardt (Head of IT and Human Resources), Dr Harald Haubitz (Head of Production), Ruud van Anraat (Chief Commercial Officer), Marcel von Ah (Chief Financial Officer) PRINCIPAL ACTIVITIES: Research, development, manufacture and distribution of speciality pharmaceuticals and value-added generics Company History: September 2008: Schweizerhall Holding AG changed its company name to Acino Holding AG. Simultaneously the business units Cimex and Novosis joined forces under the common company name Acino Subsidiary Companies: (100% owned unless stated): Acino AG (Germany); Acino Pharma AG; Acino Pharma GmbH (Germany); Acino Pharma Inc (USA); Acino Supply AG Principal Banks: UBS; CS Auditors: PricewaterhouseCoopers AG Ticker Symbol: ACIN Stock Exchange: Swiss ISIN: CH0002159413 Status: Public Company Principal Shareholders: Chase Nominees Ltd, UK (18.2%); Marianne and Dr Hans-Peter Schär (8.2%) No of Employees: 443 (Group) Financial Information: Consolidated figures 31.12.09 31.12.10 EUR’000 EUR’000 Revenue 158,181 127,533 Profit (loss) before tax 41,837 (6,027) Profit after tax 33,501 4,518 Earnings per share 10.53EUR 1.42EUR Share capital 823 823 Shareholders’ equity 256,017 252,585

03591 ACTAVIS Actavis Group Address: Turmstrasse 24, 6300 Zug International tel: +41 (41) 462 73 00 Website: www.actavis.com Company Registration Number: CH-170.9.001.398-2 Executive Board: Dr Claudio Albrecht (Chief Executive Officer), Gunnar A Beinteinsson (Executive Vice President. Human Resources and OD), Doug Boothe (Executive Vice President, Americas Sales), Gudbjorg Edda Eggertsdottir (President Iceland, Strategic Projects), Guðrun S Eyjolfsdottir (Executive Vice President, Quality and Compliance), Mark Keatley (Executive Vice President, Finance), Wolter Kuizinga (Executive Vice President, Business Development), Roy Papatheodorou (Executive Vice President and General Counsel), Preter Prock (Deputy Chief Executive Officer),

464

SWITZERLAND Valur Ragnarsson (Executive Vice President, Third-Party Sales), Lars Ramneborn (Executive Vice President, Europe Sales), Jeff Rope (Executive Vice President of Operations), Frank Staud (Executive Vice President - Corporate Communications, Branding and Sponsoring), Stefan J Sveinsson (Executive Vice President, Research and Development), Hordur Thorhallsson (Executive Vice President, MEA and Asia Pacific Sales) PRINCIPAL ACTIVITIES: Production of generic pharmaceuticals Company History: The company was privatised in 2007. In May 2011 it moved its headquarters to Switzerland Branch Offices: Bulgaria; Iceland; India; Indonesia; Italy; Malta; PRC; Romania; Russia; Serbia; UK; USA Subsidiary Companies: (100% owned unless stated): Actavis Deutschland GmbH & Co KG (Germany); Actavis EAD (Bulgaria); Actavis Operations EOOD (Bulgaria); Actavis Pharma Development Centre Private Limited (India); Actavis Romania SRL (Romania); Actavis UK Limited (UK) Status: Private Company Date of Establishment: 1956 No of Employees: 10,000 (Worldwide)

03592 ACTELION PHARMACEUTICALS LTD Address: Gewerbestrasse 16, 4123 Allschwil International tel: +41 (61) 565 65 65; +41 (61) 487 34 58 (Media/Investor Contacts) International fax: +41 (61) 565 65 00 Company email: [email protected];[email protected] Website: www.actelion.com Company Registration Number: CH-280.3.003.028-8 Board of Directors: Jean-Pierre Garnier (Chairman), JeanPaul Clozel (Chief Executive Officer), Juhani Anttila (Director), Robert Bertolini (Director), Marian Borovsky (Senior Vice President, Group General Counsel and Corporate Secretary), Robert E Cawthorn (Director), Carl Feldbaum (Director), Werner Henrich (Director), Michael Jacobi (Director), Armin Kessler (Director), Jean Malo (Director) Executive Committee: Christian Albrich (Senior Vice President and Head of Global Human Resources), Guy Braunstein (Executive Vice President and Head of Clinical Development), Roland Haefeli (Senior Vice President and Head of Investor Relations and Public Affairs) Management Board: Simon Buckingham (Senior Global Advisor), Louis de Lassence (Vice President and Head of Corporate Services), Nicholas Franco (Executive Vice President and Chief Business Development Officer), Isaac Kobrin (Senior Vice President and Chief Medical Officer), Andrew J Oakley (Executive Vice President and Chief Financial Officer), Otto Schwarz (Executive Vice President and Chief Operating Officer) PRINCIPAL ACTIVITIES: Bio-pharmaceutical company focusing on the research, development and marketing of synthetic small molecule drugs to treat and prevent diseases related to the endothelium. Actelion Ltd is the holding and finance company of the Group. Actelion Pharmaceuticals Ltd, based in Allschwil, a 100% subsidiary of Actelion Ltd, is in charge of the discovery, development, registration, production, quality assurance, safety, marketing coordination, group management and coordination. Actelion Pharmaceuticals Ltd further holds the intellectual property rights of the Group Trade Names: Tracleer (R), Ventavis (R), Zavesca (R) Subsidiary Companies: (100% owned unless stated): Actelion Clinical Research Inc (USA); Actelion Cyprus Ltd (Cyprus); Actelion Finance SCA (Luxembourg); Actelion Ilac Ticaret LS (Turkey); Actelion Luxembourg SARL (Luxembourg); Actelion One SA (Luxembourg); Actelion Participation GmbH; Actelion Partners SNC (Luxembourg); Actelion Pharma Polska Sp zoo (Poland); Actelion Pharma Schweiz AG; Actelion Pharmaceuticals Australia Pty Ltd (Australia); Actelion Pharmaceuticals Austria GmbH (Austria); Actelion Pharmaceuticals Belgium NV (Belgium); Actelion Pharmaceuticals Canada Inc (Canada); Actelion Pharmaceuticals CZ sro (Czech Republic); Actelion Pharmaceuticals Deutschland GmbH (Germany); Actelion Pharmaceuticals do Brasil Ltda (Brazil); Actelion Pharmaceuticals España SL (Spain); Actelion Pharmaceuticals France SASU (France); Actelion Pharmaceuticals Hellas SA (Greece); Actelion Pharmaceuticals Hungaria LLC (Hungary); Actelion Pharmaceuticals India Private Ltd (India); Actelion Pharmaceuticals Israel Ltd (Israel); Actelion Pharmaceuticals Italia Srl (Italy); Actelion Pharmaceuticals Japan Ltd (Japan); Actelion Pharmaceuticals Korea Ltd (South Korea); Actelion

Pharmaceuticals Ltd (CH); Actelion Pharmaceuticals Mexico SA de CV (Mexico); Actelion Pharmaceuticals Nederland BV (Netherlands); Actelion Pharmaceuticals Portugal (Portugal); Actelion Pharmaceuticals RUS LLC (Russia); Actelion Pharmaceuticals (Shanghai) Company Ltd (People’s Republic of China); Actelion Pharmaceuticals Singapore Pte Ltd (Singapore); Actelion Pharmaceuticals SK sro (Slovakia); Actelion Pharmaceuticals Sverige AB (Sweden); Actelion Pharmaceuticals Taiwan Ltd (Taiwan); Actelion Pharmaceuticals UK Ltd (UK); Actelion Pharmaceuticals US Inc (USA); Actelion Re SA (Luxembourg); Actelion Registration Ltd (UK); Actelion US Holding Company (USA); Areus Inc (USA); CoTherix Inc (USA) Auditors: Ernst & Young AG Ticker Symbol: ATLN Stock Exchange: Swiss ISIN: CH0010532478 Status: Public Company Date of Establishment: 1997 No of Employees: 1,600 (Group worldwide) Financial Information: Consolidated figures 31.12.10 31.12.11 SF’000 SF’000 Revenue 1,928,969 1,796,063 Profit (loss) before tax 440,861 (69,301) Profit (loss) after tax 390,557 (146,319) Earnings (loss) per share 3.28SF (1.23SF) Share capital 64,912 65,232 Shareholders’ equity 1,795,204 1,510,454

03593 ADD TECHNOLOGIES AG Former name: ADD Advanced Drug Delivery Technologies AG Address: Kägenstrasse 17, 4153 Reinach International tel: +41 (61) 715 97 00 International fax: +41 (61) 715 97 01 Company email: [email protected] Website: www.addtechnologies.com Company Registration Number: CH-280.3.000.972-7 Board of Directors: Reinhard Nowak (Chairman), Dr Hans Leuenberger (Director), Hans Rudolf Lötscher (Director), Jay Nowak (Director) PRINCIPAL ACTIVITIES: Development, manufacture and sale of enhanced pharmaceutical and biopharmaceutical multiparticulate products Company History: The company was previously known as ADD Advanced Drug Delivery Technologies AG Auditors: Testor Treuhand Status: Private Company Principal Shareholders: Glatt Pharmaceutical Services

03594 ADDEX PHARMACEUTICALS LTD Addex Pharma SA Address: 12 chemin des Aulx, 1228 Plans-les-Ouates International tel: +41 (22) 884 15 55 International fax: +41 (22) 884 15 56 Company email: [email protected] Website: www.addexpharma.com Company Registration Number: CH-660.0.659.007-3 Board of Directors: André J Mueller (Chairman), Vincent Lawton (Vice Chairman), Andrew Galazka (Director), Dr Raymond Hill (Director), Dr Hoyoung Huh (Director), Oleg Nodelman (Director), Antoine Papiernik (Director) Management: Dr Bharatt Chowrira (President and Chief Executive Officer), Tim Dyer (Chief Financial Officer), Dr Laurent Galibert (Head of Metabolism and Inflammation Projects), Charlotte Keywood (Chief Medical Officer), Robert Lütjens (Head of Biology), Chris Maggos (Head of Investor Relations and Communication), Dr Sonia Poli (Head of Non-Clinical Development and CNS Projects), Tatiana PontCarteret (Head of Human Resources), Jean-Philippe Rocher (Head of Chemistry) PRINCIPAL ACTIVITIES: Development, production and marketing of drugs and medicines for the treatment of addictions, physical ailments and neuropsychiatric conditions. The company develops allosteric modulators, small molecule therapeutic agents that may offer more sophisticated ways to normalise biological signalling perturbed by disease compared to classical “orthosteric” agonist or antagonist drugs. Addex focuses on the discovery and development of allosteric modulators which target G-Protein Coupled

04139 INTERVET COLOMBIA LTDA Financial Information: Sales turnover Profit before tax Profit after tax Share capital Shareholders’ equity

Financial Information: 31.12.09 COP’000 283,304,936 19,895,040 11,551,519 38,409,684 160,815,558

31.12.10 COP’000 332,030,284 39,974,950 27,291,319 38,409,684 175,383,976

04139 INTERVET COLOMBIA LTDA Address: Avenida Carrera 68 N0 17-64, Costado Occidental, Bogotá DC International tel: +57 (1) 417 5466 International fax: +57 (1) 676 1080 Website: www.intervet.com.co Company Registration Number: 830015923 Management: Angelo Bolis Delair (Representante Legal), Steven Koehler (Gerente), Ricardo Rodriguez Chala (Contador), Michiel Stijn (Gerente) PRINCIPAL ACTIVITIES: Wholesale trade in animal healthcare products Parent Company: Merck & Co Inc., USA Status: Limited Liability Company Principal Shareholders: Merck & Co Inc., USA Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 26,164,750 41,509,987 Profit before tax 1,626,129 5,345,163 Profit after tax 943,607 3,505,693 Share capital 777,550 777,550 Shareholders’ equity 3,740,314 7,064,340

04140 JOHNSON & JOHNSON DE COLOMBIA S.A. J&J DE COLOMBIA SA Address: Apartado Postal 6530, Calle 15 No.31-146, Yumbo, Valle del Cauca International tel: +57 (2) 651 3333 International fax: +57 (2) 651 3462 Website: www.jnjcolombia.com.co Company Registration Number: 890101815 Board of Directors: Martha Lucia Echeverry Piñeres (Director), Walter Grundy (Director), Adolfo Ignacio Ibarra Garcia (Director), Rosana Padilla Guevara (Representante Legal), Álvaro Palacio Restrepo (Gerente) Management: Luis Casallas Jimenez (Contador) PRINCIPAL ACTIVITIES: Manufacture of toiletries and pharmaceuticals Parent Company: Johnson & Johnson, USA Status: Non Quoted Public Company Principal Shareholders: Johnson & Johnson, USA Date of Establishment: 5 December 1962 Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 618,617,523 661,504,288 Profit before tax 67,776,661 68,557,686 Profit after tax 42,723,961 46,464,929 Share capital 1,852,846 1,852,846 Shareholders’ equity 287,559,498 282,683,276

04141 LABORATORIOS BAXTER S.A. Address: Apartado Postal 2446, Calle 36 No.2C-22, Cali International tel: +57 (2) 444 7275; +57 (2) 444 7000 International fax: +57 (2) 444 7412 Website: www.latinoamerica.baxter.com/colombia Company Registration Number: 890300292 Management: Mario Ciardelli Medina (Representante Legal), César Augusto González Ospina (Gerente), Carlos Alberto Roldan Aragon (Gerente), Hector Fauro Vargas Gutierrez (Contador) PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals Parent Company: Baxter International Inc, USA Status: Non Quoted Public Company Principal Shareholders: Baxter International Inc, USA

536

COLOMBIA

Sales turnover Profit before tax Profit after tax Share capital Shareholders’ equity

31.12.09 COP’000 525,103,917 122,665,101 83,187,057 1,000,926 465,921,888

31.12.10 COP’000 547,374,636 159,258,131 107,577,164 1,000,926 493,688,083

04142 MERCK S.A. Address: Calle 10 No. 65 28, Bogotá DC International tel: +57 (1) 425 4770 International fax: +57 (1) 420 7819 Company email: [email protected] Website: www.merck.com.co Company Registration Number: 860000580 Board of Directors: Hernán Alfonso Briceño Rodríguez (Representante Legal), Carlos Arturo García Montoya (Director), Esteban Serrano Luciano (Director) Management: Luz Mery López Lagos (Gerente), Gladys Stella Lorenzana Huertas (Contador) PRINCIPAL ACTIVITIES: Manufacture of chemicals for use in the pharmaceutical and of pharmaceutical preparations Parent Company: Merck KGaA (02705) Status: Non Quoted Public Company Principal Shareholders: Merck KGaA, Germany Date of Establishment: 1957 No of Employees: 523 Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 320,061,690 278,006,162 Profit before tax 73,916,856 37,215,672 Profit after tax 50,079,535 24,879,572 Share capital 14,356,030 14,356,030 Shareholders’ equity 124,538,491 105,894,170

04143 NOVARTIS DE COLOMBIA S.A. NOVARTIS

PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals for human and veterinary use Parent Company: Pfizer Inc, USA Status: Non Quoted Public Company Principal Shareholders: Pfizer Inc, USA Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 280,354,399 472,014,510 Profit before tax 32,416,267 21,092,880 Profit after tax 18,947,634 13,203,872 Share capital 30,332,357 30,332,357 Shareholders’ equity 91,080,461 81,304,138

04145 PROCTER & GAMBLE COLOMBIA LTDA P & G Colombia Ltda Address: Apartado Postal 94611, Carrera 7 No.114-33, Piso 12, Bogotá DC International tel: +57 (1) 520 8000 International fax: +57 (1) 640 0013 Website: www.pg.com Company Registration Number: 800000946 Management: Carlos Alfredo Giraldo Aly (Representante Legal), Rafael Molina (Contador), Juan David Valencia Ocampo (Gerente), Víctor Karlo Velazquez Patron (Gerente) PRINCIPAL ACTIVITIES: Wholesale trade in personal care products, household cleaning items, laundry detergents, prescription drugs and disposable nappies Trade Names: Ariel, Pantele, Pert Plus, Camay, Crest Parent Company: Procter & Gamble Company, USA Status: Limited Liability Company Principal Shareholders: Procter & Gamble Company, USA Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 691,831,680 753,006,926 Profit before tax 20,194,656 65,237,458 Profit after tax 8,916,973 42,511,884 Share capital 32,212,968 32,212,968 Shareholders’ equity 194,600,815 200,152,052

Address: Apartado Postal 123234, Calle 11 No.65-51, Bogotá DC International tel: +57 (1) 654 4444 International fax: +57 (1) 446 4815 Website: www.novartis.com Company Registration Number: 860002538 Board of Directors: Maria Cristina Alvarez Rodriguez (Representante Legal), Jean Claude Dubos (Director), Carlos Dicken Garcia Iragorri (Director) Management: Carlos Leonardo Garcia Hewitt (Gerente), Evelyn Peña (Contador), Guillermo José Quintero Perdomo (Gerente) PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals aiming to prevent and cure diseases, to ease suffering and to enhance the quality of life Parent Company: Novartis AG (03653) Status: Non Quoted Public Company Principal Shareholders: Novartis AG, Switzerland (100%) Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 321,017,516 361,448,213 Profit before tax 19,983,915 38,131,536 Profit after tax 13,739,070 23,252,553 Share capital 7,934,807 7,934,807 Shareholders’ equity 113,709,095 100,584,514

Address: Carrera 44 No.17-21, Bogotá DC International tel: +57 (1) 417 8860 International fax: +57 (1) 337 9270 Website: www.roche.com.co Company Registration Number: 860003216 Board of Directors: Hector Feliu (Director), Rolf Erik Honger (Representante Legal), Jorg Michael Rupp (Director) Management: Rodrigo Alonso Gómez Burbano (Gerente), Edith Marisol López Borbón (Contador) PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals Parent Company: Roche Holding AG (03668) Status: Non Quoted Public Company Principal Shareholders: Roche Holding AG, Switzerland (100%) Financial Information: 31.12.09 31.12.10 COP’000 COP’000 Sales turnover 553,829,987 556,832,268 Profit before tax 26,838,624 11,262,446 Profit after tax 18,173,009 9,224,135 Share capital 26,923,689 26,923,689 Shareholders’ equity 202,200,282 218,813,820

04144 PFIZER S.A. PFIZER

04147 SANOFI-AVENTIS PHARMA S.A. SANOFI

Address: Avenida El Dorado No.68B-85, Bogotá DC International tel: +57 (1) 417 8507 International fax: +57 (1) 427 0070 Website: www.pfizer.com.co Company Registration Number: 860039561 Board of Directors: Luis Alberto Acuña González (Director), Luis Fernando Molano (Director), Francisco A Rodríguez Rodríguez (Director) Management: Juan Carlos Avila Bustos (Contador), Claudia Johanna Bohorquez Leon (Gerente), Andres Jordan Herrera (Representante Legal)

Address: Apartado Postal 6161, Transversal 23 N. 97-73, Piso 9, Bogotá DC International tel: +57 (1) 621 8400 International fax: +57 (1) 621 4400 Website: www.sanofi-aventis.com Company Registration Number: 830010337 Board of Directors: Mauricio Botero Caicedo (Representante Legal), Stephen Edward Cobhan Scott (Director), Jesus Hernando Cubides Ballesteros (Director) Management: Giovanni Castillo Moreno (Contador), Hernando Suárez Ramírez (Gerente)

04146 PRODUCTOS ROCHE S.A.

Alphabetical Index

Alphabetical Index

Alphabetical Index 3M Australia Pty Ltd [Australia] 3M Deutschland GmbH [Germany ] 3M India Limited [India] 3M Ireland Ltd [Republic of Ireland ] 3M Manufacturera Venezolana S.A. [Venezuela] 3M Singapore Pte Ltd [Singapore] 3M Taiwan Ltd [Taiwan] 3M United Kingdom PLC [UK ] 77 Elektronika Kft [Hungary ] A Baur & Co Ltd [Sri Lanka] A C Nielsen [India] A Nelson & Co Ltd [UK ] A S Bryden & Sons (Antigua) Ltd [Antigua and Barbuda] A S Bryden & Sons (Trinidad) Limited [Trinidad and Tobago] A S Bugshan & Bros [Saudi Arabia] A Vogel Bioforce AG [Switzerland ] A&D Pharma Holdings SRL [Romania] A. Cardoso, S.A. [Spain] A. Menarini Industrie Farmaceutiche Riunite Srl [Italy ] A.S. Bryden & Sons (Barbados) Ltd [Barbados] A2 Corporation Limited [New Zealand ] AAH Pharmaceuticals Ltd [UK ] AAIPharma Services Corp. [USA] Aalto Bio Reagents Ltd [Republic of Ireland ] Aamal Company QSC [Qatar ] Aarti Drugs Limited [India] AB Cosmetics, s.r.o. [Slovakia] AB Kozmetika group sro [Slovakia] AB Sanitas [Lithuania] AbacusBio Limited [New Zealand ] Abbot [India] ABBOTT [Spain] Abbott Argentina S.A. [Argentina] Abbott Australasia Pty Limited [Australia] Abbott Belgique/België [Belgium] Abbott Científica SA [Spain] Abbott France SAS [France] Abbott GmbH & Co KG [Germany ] Abbott Healthcare Products BV [Netherlands] Abbott Healthcare SAS [France] Abbott India Limited [India] Abbott Japan Co Ltd [Japan] Abbott Korea Ltd [South Korea] Abbott Laboratories [USA] Abbott Laboratories A/S [Denmark ] Abbott Laboratories Argentina SA [Argentina] Abbott Laboratories de Colombia S.A. [Colombia] Abbott Laboratories de México, S.A. de C.V. [Mexico] Abbott Laboratories (Hellas) SA [Greece] Abbott Laboratories Ltd [UK ] Abbott Laboratories (Malaysia) Sdn Bhd [Malaysia]

00480 02548 00641 03281 04265 01538 01732 03719 02824 01725 00642 03720 04057 04097 00330 03606 03334 03382 03004 04066 01214 03721 04371 03282 00324 00643 03357 03357 03059 01215 00644 03384 03909 00481 02084 03383 02300 02549 03068 02301 00644 00962 01585 04372 02201 03909 04131 04172 02789 03722 01137

Abbott Laboratories Pakistan Limited [Pakistan] Abbott Laboratories Philippines [Philippines] Abbott Laboratories (Singapore) Pte Ltd [Singapore] Abbott Laboratories Vascular Enterprises Limited [Republic of Ireland ] Abbott Laboratories, Ross Products Div. [USA] Abbott Laboratories, S.A. [Spain] Abbott Laboratórios do Brasil Ltda [Brazil] Abbott Laboratorios Lda [Portugal] Abbott Liestal AG [Switzerland ] Abbott Logistics BV [Netherlands] Abbott Logistics BV Zwolle [Netherlands] Abbott Norge AS [Norway ] Abbott Oy [Finland ] Abbott Pharmaceuticals Puerto Rico Ltd [Puerto Rico] Abbott Products SA/NV [Belgium] Abbott Products SAS [France] ABBOTT S.A. [Colombia] Abbott SA/NV [Belgium] Abbott Scandinavia AB [Sweden] Abbott Service AG [Switzerland ] Abbott South Africa (Pty) Ltd [South Africa] Abbott Srl [Italy ] Abcam Plc [UK ] Abdbullah Mohd Almadani Alghamdi Est [Saudi Arabia] Abdel Moniem Group of Companies [Sudan] Abdellatif Banaja & Co [Saudi Arabia] Abdi Ibrahim Ilaç Sanayi ve Ticaret AS [Turkey ] Abdullah Said Bugshan & Bros [Saudi Arabia] Abdullatif MS Jamjoom & Bros [Saudi Arabia] Abdulrehman Algosaibi General Trading Bureau [Saudi Arabia] Abengoa, S.A. [Spain] ABIC Biological Laboratories Ltd [Israel] ABIC Veterinary Products Ltd [Israel] ABLE C & C Inc [South Korea] Able Sales Company Inc. [Puerto Rico] Ablynx SA/NV [Belgium] Abraxis BioScience Inc. [USA] Abu Shakra [Jordan] Abu Shakra Trading Agency [Jordan] Aburaihan Pharmaceutical Company [Iran] ACAPI [Egypt ] ACB Blocks [Russia] Accelciors CRO and Consultancy Services Limited Company [Hungary ] Accelsiors Kft [Hungary ]

01243 01499 01539 03283 04373 03384 03948 03236 03589 03069 03069 03123 02266 04085 02083 02302 04131 02084 03526 03589 00079 02938 03723 00385 00396 00386 03693 00330 00373 00331 03385 02885 02885 01586 04086 02085 04374 00232 00232 00932 00174 01907 02825 02825

Accelsiors Kutatásszervezõ és Tanácsadó Szolgáltatási Kft [Hungary ] Acciona, S.A. [Spain] Accredo Health, Inc. [USA] ACE BioSciences A/S [Denmark ] ACEnet [Canada] ACES [United Arab Emirates] Aché Laboratórios Farmacêuticos S.A. [Brazil] ACI Limited [Bangladesh] ACIdEKA, S.A. [Spain] Acino AG [Germany ] Acino Holding AG [Switzerland ] ACNielsen Ltda [Brazil] ACNielsen SA [Greece] ACNielsen, a VNU business [Cyprus] ACNielsen/AMER World Research [Cyprus] Acorda Therapeutics Inc. [USA] Acorn Products (Pty) Ltd [South Africa] ACP Pharma S.A. [Poland ] Acraf SpA [Italy ] Acromax Dominicana S.A. [Dominican Republic] Acta Service Srl [Italy ] Actavis [Switzerland ] Actavis Deutschland GmbH & Co KG [Germany ] Actavis EAD [Bulgaria] Actavis Group [Switzerland ] Actavis Operations EOOD [Bulgaria] Actavis Pharma Development Centre Private Limited [India] Actavis Romania SRL [Romania] Actavis UK Limited [UK ] Actelion Pharmaceuticals France SASU [France] Actelion Pharmaceuticals Ltd [Switzerland ] Active Biotech AB [Sweden] AD Jaka 80 Radovis [Macedonia] AD Motors Co Ltd [South Korea] Adamed Sp. z.o.o. [Poland ] ADCO [Egypt ] Adcock Ingram Holdings Limited [South Africa] ADD Advanced Drug Delivery Technologies AG [Switzerland ] ADD Technologies AG [Switzerland ] Addex Pharma SA [Switzerland ] Addex Pharmaceuticals Ltd [Switzerland ] Addis Pharmaceutical Factory [Ethiopia] ADI Finechem Limited [India] ADImmune Corporation [Taiwan] Adinath Bio-Labs Limited [India] adinotec AG [Germany ] Adisseo France SAS [France] ADL [India] ADL [India] AdnaGen GmbH [Germany ] Adnan Shalan & Co [Jordan]

02825 03386 04375 02202 04291 00442 03949 00547 03387 02550 03590 03950 02790 02159 02159 04376 00080 03158 02939 04071 02940 03591 02551 02142 03591 02143 00645 03333 03724 02303 03592 03527 01900 01587 03159 00183 00081 03593 03593 03594 03594 00012 00646 01733 00647 02552 02304 00643 00759 02553 00233

Adroit Medical Systems Inc. [USA] Advanced Biochemicals Ltd [India] Advanced Chemical Industries Ltd [Bangladesh] Advanced Enzyme Technologies Ltd [India] Advanced Technology Company KSCC [Kuwait ] Advik Laboratories Limited [India] Advinus Therapeutics Limited [India] ADWYA SA [Tunisia] Aekyung Industrial Co Ltd [South Korea] Aerocrine AB [Sweden] Aerospace Corp. [USA] Aerospace Equipment Corporation Joint Stock Company [Russia] AES Chemunex SA [France] AEterna Zentaris Inc. [Canada] Aeterna Zentaris Inc. [Canada] AFDIL [India] Afework International Group plc [Ethiopia] Affitech A/S [Denmark ] Affymax Inc. [USA] Aflofarm Fabryka Leków Sp. z.o.o. [Poland ] Aflofarm Farmacja Polska Sp. z.o.o. [Poland ] AFM SpA [Italy ] Afri Medical [Egypt ] Africom Lda [Mozambique] AGA Healthcare SA [Brazil] AGECA Ethiopia Company Pvt Ltd [Ethiopia] Agennix AG [Germany ] Aggad Investment Company [Saudi Arabia] AGI Therapeutics plc [Republic of Ireland ] Agilent Technologies Deutschland GmbH [Germany ] Agilent Technologies Singapore (Holdings) Pte Ltd [Singapore] Agilent Technologies Singapore Pte Ltd [Singapore] Agis Industries (1983) Ltd [Israel] AGOC [Sudan] Agostini’s Ltd [Trinidad and Tobago] Agouron Pharmaceuticals Inc. [USA] AGOWA Gesellschaft für molekularbiologische Technologie mbH [Germany ] AgResearch Limited [New Zealand ] Agricare Ltd [Ghana] Agricultural Research Council [South Africa] AGRIMEX LTD Sp. z.o.o. [Poland ] Agripac S.A. [Ecuador ] Agroceres Ltda [Brazil] Agrolab GmbH [Germany ] Agropalma S.A. [Brazil] Agropecuaria de Guissona, S.C.L. [Spain]

04377 00648 00547 00648 00256 00649 00650 00428 01588 03528 04378 01908 02305 04292 04293 00663 00013 02203 04379 03160 03161 02941 00175 00052 04020 00014 02554 00332 03284 02555 01540 01541 02923 00396 04098 04380 02686 01216 00020 00082 03162 04159 03951 02556 03952 03388

595

Index by Country

Index by Country

Index by Country Albania IMI FARMA Sh.p.k.

01867

Algeria Antibiotical SPA Laboratoire Biopharm Algérie SPA Biotic SPA DIPROCHIM SPA Entreprise de Distribution de Produits Chimiques SPA Entreprise Nationale de Production Pharmaceutique Groupe Blanky SPA Groupe Industrial Saidal SPA Nedromeubles SPA Pharmal SPA Promeuble Sarl Sanofi-Aventis Algeria SPA

00162 00163 00164 00165 00165 00167 00166 00167 00168 00169 00170 00171

Angola PETROGAL Angola, Lda

00001

Argentina Abbott Argentina S.A. Abbott Laboratories Argentina SA Air Liquide Argentina S.A. Alcon Laboratorios Argentina S.A. AstraZeneca Argentina S.A. BASF Argentina S.A. Bayer Argentina S.A. Beiersdorf S.A. Biocientífica S.A. Bristol-Myers Squibb Argentina S.R.L. Centro Oncológico Buenos Aires Chemotécnica S.A. Chemotécnica Sintyal SA Drogueria del Sud S.A.C.I. Elvetium SA GlaxoSmithKline Argentina S.A. Grifols Argentina S.A. Grupo Sidus Instituto Rosenbusch S.A. de Biologia Experimental Agropecuaria Invap S.A. Ivax Argentina S.A. Johnson y Sons de Argentina Laboratorio Elea S.A.C.I.F. y A. Laboratorios Bagó S.A. Laboratorios Glaxo Argentina S.A.C.I. Laboratorios Phoenix S.A.I.C. y F. L’Oréal Argentina S.A. Medicus S.A. Merck Química Argentina S.A.I.C. Novartis Argentina S.A. Novartis S.A. NuclearLab S.R.L. Nycomed S.A. Pioneer Argentina SA

03909 03909 03910 03911 03912 03913 03914 03915 03916 03917 03918 03919 03919 03920 03926 03921 03922 03923 03924 03925 03926 03940 03927 03928 03921 03929 03930 03931 03932 03933 03933 03934 03935 03936

Quintiles Argentina SA Productos Roche S.A.Q. e I. Laboratorios Roemmers S.A.I.C. y F. S.C. Johnson & Son de Argentina S.A.I.C. Tecnolab S.A. Unilever de Argentina S.A. Wiener Laboratorios S.A.I.C.

03937 03938 03939 03940 03941 03942 03943

Armenia Arpimed Pharmaceutical Enterprise BIO-VAR Ltd Erevan Chemical-Pharmaceutical Joint Stock Company Liqvor Pharmaceuticals

01868 01869 01870 01871

Australia 3M Australia Pty Ltd Abbott Australasia Pty Limited AGT Biosciences Ltd Alchemia Limited Alphapharm Pty Ltd Anadis Limited Analytica Limited ANSTO Astra Pharmaceuticals Pty Ltd AstraZeneca Pty Ltd Ausmelt Limited Australian Nuclear Science & Technology Organisation Australian Pharmaceutical Industries Limited Beiersdorf Australia Ltd BioDiem Ltd Bionomics Limited Biota Holdings Limited Blackmores Limited Boehringer Ingelheim Pty Limited Bristol-Myers Squibb Australia Pty Ltd BTF Pty Ltd Cellestis Limited ChemGenex Pharmaceuticals Limited Circadian Technologies Limited Clariant (Australia) Pty Ltd CSL Limited Eli Lilly Australia Pty Limited Genetic Technologies Limited GlaxoSmithKline Australia Pty Ltd Healthzone Limited IDT Australia Limited Immuron Limited Implicit Biosciences Ltd Institute of Drug Technology Australia Ltd Intervet Australia Pty Limited S C Johnson & Son Pty Ltd Johnson & Johnson Pacific Pty Limited Lipa Pharmaceuticals Limited McCormick Foods Australia Pty Ltd

00480 00481 00497 00482 00483 00506 00484 00486 00485 00485 00526 00486 00487 00488 00489 00490 00491 00492 00493 00494 00495 00496 00497 00498 00499 00500 00501 00502 00503 00504 00505 00506 00507 00505 00508 00509 00510 00511 00512

Meat & Livestock Australia Limited Mentholatum Australasia Pty Ltd Merck Sharp & Dohme (Australia) Pty Ltd Metabolic Pharmaceuticals Limited Calzada Limited MLA Monsanto Australia Limited MSD Nichirei Australia Pty Ltd Nippon Steel Australia Pty Limited Novartis Pharmaceuticals Australia Pty Limited Novo Nordisk Pharmaceuticals Pty Limited Novogen Limited Nufarm Limited Nutrimetics International Holdings Pty Ltd Orica Limited Outotec Pty Ltd Pfizer Australia Pty Ltd PharmaCare Laboratories Pty Limited Pharmaxis Ltd Phosphagenics Limited Prana Biotechnology Limited Primary Health Care Ltd Proteome Systems Limited Provet Holdings Ltd PZ Cussons Australia Pty Ltd James Richardson Corporation Pty Ltd Ridley Corporation Ltd Roche Products Pty Limited Sanofi Australia and New Zealand Sanofi-Aventis Australia Pty Limited SGS Australia Pty Ltd Sigma Company Limited Sigma Pharmaceuticals Limited Silex Systems Limited Sirtex Medical Limited Sonic Healthcare Limited Washington H Soul Pattinson & Company Limited Tyrian Diagnostics Limited Virax Holdings Limited

00513 00514 00515 00516 00516 00513 00517 00515 00518 00519 00520 00521 00522 00523 00524 00525 00526 00527 00528 00529 00530 00531 00532 00545 00533 00534 00535 00536 00537 00538 00538 00539 00540 00540 00541 00542 00543 00544 00545 00546

Austria AstraZeneca Österreich GmbH Aventis Pasteur MSD GmbH Aventis Pharma GmbH BASF Performance Products GmbH Baxter Aktiengesellschaft Bayer Austria Gesellschaft mbH Beiersdorf Gesellschaft mbH Boehringer Ingelheim Austria GmbH Boehringer Ingelheim RCV GmbH & Co KG Boehringer Ingelheim Regional Centre Vienna GmbH & Co KG C Richter Ges mbH & Co KG Parfums Christian Dior GmbH dm drogerie markt GmbH

02045 02079 02080 02046 02047 02048 02049

EBEWE Arzneimittel GmbH EBEWE Pharma Ges mbH NfG KG F Joh Kwizda UnternehmensVerwaltungsgesellschaft mbH Fresenius Kabi Austria GmbH Geoconsult ZT GmbH GKB-Bergbau GmbH GlaxoSmithKline Österreich GlaxoSmithKline Pharma GmbH Guerlain Gesellschaft mbH H Wilhelm Schaumann Gesellschaft mbH & Co KG Henkel Austria Gruppe Beteiligungsverwaltung Gesellschaft mbH Henkel CEE Gesellschaft mbH Henkel Central Eastern Europe Gesellschaft mbH Herba Chemosan Apotheker-AG Hestag Arzneiwarengrosshandlung Ges mbH Hoffmann-La Roche Wien Ges mbH Intercell AG INTERCELL Biomedizinische Forschungs- und Entwicklungs AG Intervet GesmbH Jacoby Pharmazeutika Aktiengesellschaft Janssen-Cilag Pharma GmbH Johnson & Johnson Gesellschaft mbH Kwizda Holding GmbH Lohmann & Rauscher GmbH Novartis Pharma GmbH Nycomed Austria GmbH ÖIAG-Bergbauholding AG Österreichische Unilever GesmbH P & G Austria GmbH Parfums Givenchy c/o Guerlain GesmbH Pfizer Corporation Austria Gesellschaft mbH Phoenix Arzneiwarengrosshandlung GmbH Procter & Gamble Austria GmbH Richter Pharma AG Roche Austria GmbH Roche Diagnostics GmbH Sandoz GmbH Sanochemia Pharmazeutika AG Sanofi Pasteur MSD GmbH Sanofi-Aventis Österreich Sanofi-Aventis GmbH Sanova Pharma GesmbH Schaumann Holding Ges mbH Unilever Austria GmbH

02053 02053 02067 02054 02055 02056 02057 02057 02058 02059 02060 02060 02060 02061 02072 02075 02062 02062 02063 02064 02065 02066 02067 02068 02069 02070 02056 02082 02073 02058 02071 02072 02073 02074 02075 02076 02077 02078 02079 02080 02080 02081 02059 02082

02050

Azerbaijan 02050 02050 02074 02051 02052

Azerbaijan Petroleum Machinery Scientific Research and Development Institute 01872 Azinmash 01872 SOCAR 01873

625